Repare Therapeutics

66 articles with Repare Therapeutics

• Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306

  3/14/2023

  Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX) today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR Annual Meeting, held April 14-19, 2023, in Orlando, Florida.

• Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

  2/28/2023

  Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022.

• Repare Therapeutics to Participate in Two Upcoming Investor Conferences - February 2, 2023

  2/2/2023

  Repare Therapeutics Inc. today announced that members of its senior management team will participate at two investor conferences in February and March.

• Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals

  1/19/2023

  Repare Therapeutics Inc. today announced that the Company has received an approximately $1.5 million (¥200 million) research service payment from Ono Pharmaceutical Co., Ltd. (“Ono”).

• Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans - December 19, 2022

  12/19/2022

  Repare Therapeutics Inc. today announced that they have established new Automatic Securities Disposition Plans (“ASDPs”), or in the case of Maria Koehler modified her existing ASDP, in accordance with applicable United States and Canadian securities legislation.

• Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

  11/9/2022

  Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2022.

• Repare Therapeutics to Participate in Two Upcoming Investor Conferences

  11/7/2022

  Repare Therapeutics Inc. today announced that members of its senior management team will participate at two investor conferences in November.

• Repare Therapeutics to Participate in Two Upcoming September 2022 Investor Conferences

  9/7/2022

  Repare Therapeutics Inc., a leading clinical-stage precision oncology company, announced that members of its senior management team will participate at two investor conferences in September.

• Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

  8/4/2022

  Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2022.

• Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference

  6/7/2022

  Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022 at 03:20 p.m. Pacific Time/ 6:20 p.m. Eastern Time in Rancho Palos Verdes, CA.

• Versant Ventures to File Early Warning Report in Respect of Repare Therapeutics Inc.

  6/6/2022

  Versant Ventures today announced it will file an early warning report with respect to the ownership of securities in Repare Therapeutics Inc.

• 

  Roche, Repare Ink $1.2B Deal for Development of Cancer Therapy

  6/2/2022

  Repare Therapeutics announced a global cancer collaboration valued at up to $1.2 billion with Swiss pharma giant Roche for the development and commercialization of camonsertib.

• Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)

  6/1/2022

  Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), today announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500).

• Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day

  5/9/2022

  Repare Therapeutics Inc. announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time.

• Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

  5/5/2022

  Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022.

• Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification

  4/20/2022

  Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification,

• 

  AACR: BMS, Repare and InvestisBio Present Compelling Data

  4/12/2022

  Hundreds of presentations on oncology research are highlighted at the AACR Annual Meeting, which is running from April 7 to 13 in New Orleans.

• Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting

  4/11/2022

  Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), today presented updated data from its ongoing Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (Ataxia-Telangiectasia mutated kinase) at the 2022 AACR Annual Meeting.

• Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting

  4/8/2022

  Repare Therapeutics Inc., a leading clinical-stage precision oncology company, announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR, as well as two additional poster presentations at the upcoming 2022 AACR Annual Meeting held in New Orleans on April 8-13, 2022.

• Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data From the Phase 1/2 TRESR RP-3500 Clinical Trial and SNiPDx Panel at the 2022 AACR Annual Meeting

  3/8/2022

  Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), today announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR trial of RP-3500 and a poster presentation of initial discovery and validation data of the novel Synthetic Lethal Interactions for Precision Diagnostics (SNiPDx) panel to understand allelic status of STEP2 genes at the upcoming 2022 AACR Annual Meeting,